DW

SEP 1 5 2005 SEP 1 5 2005 IN

Atty. Docket No.:

4231/2032

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Liew et al.

Serial No.:

10/649,959

Filed:

August 26, 2003

Entitled:

Beta-2 Microglobulin (B2M) and

B2M Related Gene Products for the

Regulation of Osteoarthritis
Pathogenesis and Chondrocyte

Proliferation

Examiner:

Danton, M.J.S.

Group Art Unit:

1634

Conf. No.

7379

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen, Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents, as well as, for the Examiner's convenience, copies of all foreign patent documents and non-patent literature are enclosed. This application was filed after June 30, 2003, and copies of U.S. patents and U.S. patent applications are not required and are not enclosed.

Pursuant to CFR § 1.97(e)(1), each item contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application or International application. Because this statement is being filed within three months of receipt of the Search Report, no fee is believed to be due. A copy of the Search Report is included and cited on the enclosed PTO-1449.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Serial No.: 10/649,959 Docket No.: 4231/2032

Page 2

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date:

Respectfully submitted,

Name: Kathleen Williams

Registration No.: 34,380 Customer No.: 29933 Palmer & Dodge LLP 111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

Atty. Docket No.:

4231/2032

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Liew et al.

Serial No.:

10/649,959

Filed:

August 26, 2003

Entitled:

Beta-2 Microglobulin (B2M) and

B2M Related Gene Products for the

Regulation of Osteoarthritis Pathogenesis and Chondrocyte

Proliferation

Examiner:

Danton, M.J.S.

Group Art Unit:

1634

Conf. No.

7379

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen Williams

Name of Person Mailing Paper

Signatur erson Mailing Paper

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. Information Disclosure Statement;
- Form PTO-1449; 2.
- 3. Copies of Cited References; and
- Return Post Card. 4.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 4231/2032. A duplicate of this transmittal letter is enclosed for this purpose.

Date: 9/13/05

Respectfully submitted,

Kathleen M. Williams

Registration No.: 34,380

Customer NoP 29933

Palmper & Dodge LLP/

111 Huntington Avenue Boston, MA 02199-75/3

Tel: 617-239-0100

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office			Attorney Docket No.		Serial No.			
INFORMATION DISCLOSURE STATEMENT			4231/2032 10/649,959					
(SEP 15 2005 Eg)			Applicant(s):. Liew et al.					
\ <u>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</u>			Filing Date: Aug. 26,	2003 Group: 1634				
U.S. PATENT DOCUMENTS								
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)		
	6,331,396B1	Dec. 18, 2001	Silverman et al.					
	6,320,022B1	Nov. 20, 2001	Cutitia et al.					
	6,444,876B1	Sept. 3, 2002	Lassner et al.					
	2001-0031757	Oct. 18, 2001	Schafer et al.					
						· · · · · · · · · · · · · · · · · · ·		
							_	
FOREIGN PATENT DOCUMENTS								
Examiner Initial	Document No.	Publication	Country	Class	Subclass	Translation		
milai		Date		 		YES	NO	
				ļ				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	Sakashita et al. (Jan. 2000) American Journal of Pathology, 156(1):227-236							
	Naot et al. (2001) Endocrinology, 142(6):1849-1857							
	Foneseca et al. (2000) British Journal of Hematology, 109:24-29							
	Connor , J.R. (2001	Connor, J.R. (2001) Oateoarthritis and Cartilage, 9:727-737						
	Copy of PCT Intern	Copy of PCT International Search Report (PCT/US03/26730)						
EXAMINER				DATE CO	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.								